Iambic Therapeutics (NASDAQ:IAM) Stock Jumps 5.6% – What’s Next?

Iambic Therapeutics, Inc. (NASDAQ:IAM – Get Free Report) shares traded up 5.6% on Tuesday. The stock traded as high as $13.00 and last traded at $12.51. Approximately 26,667 shares were traded during trading, a decline of 96% from the average session volume of 690,737 shares. The stock had previously closed at $11.85.

Analysts Set New Price Targets

A number of research analysts recently weighed in on the stock. JPMorgan Chase & Co. assumed coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They set an “overweight” rating and a $22.00 price objective on the stock. Bank of America assumed coverage on shares of Iambic Therapeutics in a research report on Monday, November 9th. They issued a “buy” rating and a $30.00 target price for the company. Zacks Research started coverage on shares of Iambic Therapeutics in a research note on Tuesday, November 10th. They set a “hold” rating for the company. Citigroup initiated coverage on Iambic Therapeutics in a report on Monday, November 9th. They set a “buy” rating and a $22.00 price target on the stock. Finally, Wall Street Zen upgraded Iambic Therapeutics to a “hold” rating in a research note on Saturday, November 7th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $27.25.

View Our Latest Research Report on IAM

Iambic Therapeutics Price Performance

Iambic Therapeutics (NASDAQ:IAM – Get Free Report) last posted its quarterly earnings data on Monday, November 16th. The company reported ($6.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.33) by ($5.90). The company had revenue of $11.35 million for the quarter, compared to the consensus estimate of $42.50 million. On average, research analysts expect that Iambic Therapeutics, Inc. will post -1.83 earnings per share for the current year.

Insider Activity at Iambic Therapeutics

In related news, Director Evan Lockwood Rachlin acquired 718,750 shares of Iambic Therapeutics stock in a transaction dated Friday, October 16th. The stock was purchased at an average cost of $16.00 per share, for a total transaction of $11,500,000.00. Following the purchase, the director directly owned 2,588,248 shares of the company’s stock, valued at approximately $41,411,968. This trade represents a 38.45% increase in their position. The purchase was disclosed in a filing with the SEC, which is accessible through this link.

Iambic Therapeutics Company Profile

(Get Free Report)

Iambic Therapeutics is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design. The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

Featured Articles

Receive News & Ratings for Iambic Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Iambic Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.